Hipoparatiroidismo: Avances Terapéuticos y Nuevas Perspectivas en la Era de la Hormona Paratiroidea Recombinante
Ibero Ciencias - Revista Científica y Académica - ISSN 3072-7197 · 17.03.2026 · 5 (1) · 3508-3518
DOI: 10.63371/ic.v5.n1.a844 ↗Kurz gefasst
Fachartikel in der Zeitschrift Ibero Ciencias - Revista Científica y Académica - ISSN 3072-7197, online erschienen am 17.03.2026. Verfasst von José Alexander Rubiano Pedroza und 2 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-SA 4.0).
Abstract (Originalsprache)
Introduction
Hypoparathyroidism is an endocrinopathy characterized by parathyroid hormone (PTH) deficiency, leading to critical calcium and phosphorus imbalances. This manifests as hypocalcemia, hyperphosphatemia, and a wide range of neuromuscular symptoms and chronic multisystem complications [1], [2]. Post-surgical iatrogenic etiology is the most common, although autoimmune and genetic forms are also relevant [3], [4]. Conventional treatment, based on calcium and vitamin D supplementation, is limited because it does not replicate PTH physiology, resulting in suboptimal calcium control, persistent symptoms, and an increased risk of renal complications, such as nephrocalcinosis and chronic kidney disease [1], [5]. Methodology: This systematic review, covering the literature from January 2020 to February 2026, employed a comprehensive search strategy in databases such as PubMed, SciELO, and Embase, under the PICO model (2550/120), focusing on etiology, pathophysiology, diagnosis, clinical manifestations, and therapeutic advances.
Results
The transformative impact of recombinant human PTH (rhPTH) replacement therapies is highlighted. rhPTH (1-84) has proven effective, reducing dependence on supplements and improving biochemical and bone control, although with warnings about potential risks [6], [7]. A significant milestone is palopegteriparatide (TransCon PTH), which has allowed a high percentage of patients to achieve independence from conventional therapy, normalize calcium and phosphorus levels, reduce calciuria, and improve renal function and quality of life [8], [9], [10].
Conclusion
Although hypoparathyroidism remains a challenge, the development of more physiological therapies such as palopegteriparatide offers an improved prognosis and optimized quality of life for patients.
Zitieren
APA
Pedroza, J. A. R., Jaramillo, J. D. J., & Conde, D. J. V. (2026). Hipoparatiroidismo: Avances Terapéuticos y Nuevas Perspectivas en la Era de la Hormona Paratiroidea Recombinante. Ibero Ciencias - Revista Científica y Académica - ISSN 3072-7197, 5(1), 3508-3518. https://doi.org/10.63371/ic.v5.n1.a844
Vancouver
Pedroza JAR, Jaramillo JDJ, Conde DJV. Hipoparatiroidismo: Avances Terapéuticos y Nuevas Perspectivas en la Era de la Hormona Paratiroidea Recombinante. Ibero Ciencias - Revista Científica y Académica - ISSN 3072-7197. 2026;5(1):3508-3518. doi:10.63371/ic.v5.n1.a844
BibTeX
@article{Pedroza2026,
author = {Pedroza, José Alexander Rubiano and Jaramillo, Juan David Jaimes and Conde, Damaris Jhojana Villamizar},
title = {Hipoparatiroidismo: Avances Terapéuticos y Nuevas Perspectivas en la Era de la Hormona Paratiroidea Recombinante},
journal = {Ibero Ciencias - Revista Científica y Académica - ISSN 3072-7197},
year = {2026},
volume = {5},
number = {1},
pages = {3508--3518},
doi = {10.63371/ic.v5.n1.a844}
}
EUVIMED